Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced that it will present at the Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 4:00 p.m. ET.
NEW HAVEN, Conn., June 01, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, today announced that it will present at the Jefferies Virtual Healthcare Conference 2020 on Thursday, June 4, 2020 at 4:00 p.m. ET.
Doug Manion, MD, CEO and Chairman of the Board of Kleo Pharmaceuticals will provide an overview of Kleo’s antibody recruiting molecule (ARMTM) and monoclonal antibody therapy enhancer (MATETM) platforms in the context of the Company’s multiple myeloma and COVID-19 programs. A link to the live webcast and replay of the Company’s presentation will be available here.
About Kleo Pharmaceuticals, Inc.
Kleo Pharmaceuticals is a unique biotechnology company developing next-generation, bispecific compounds designed to emulate or enhance the activity of biologics based on the groundbreaking research of its scientific founder Dr. David Spiegel at Yale University. Kleo’s compounds are designed to direct the immune system to destroy cancerous or virally infected cells and are currently in development for the treatment of various diseases, including multiple myeloma and COVID-19. Compared to biologics, Kleo’s compounds are smaller and more versatile, leading to potentially improved safety and efficacy. They are also much faster and more efficient to design and produce, particularly against novel targets. Kleo develops drug candidates based on its proprietary technology platforms, all of which are modular in design and enable rapid generation of novel immunotherapies that can be optimized against specified biological targets and combined with existing cell- or antibody-based therapies. These include Antibody Recruiting Molecules (ARMs) and Monoclonal Antibody Therapy Enhancers (MATEs). Biohaven Pharmaceutical Holding Company (NYSE:BHVN) and PeptiDream Inc. (TYO:4587) are investors in Kleo Pharmaceuticals. For more information visit http://kleopharmaceuticals.com.
Forward-Looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company’s management. All statements, other than statements of historical facts, included in this press release regarding the Company’s plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words “estimate,” “project,” “intend,” “expect,” “believe,” “anticipate,” “will,” “plan,” “could,” “may” and similar expressions are intended to identify forward-looking statements. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT INFORMATION
LifeSci Advisors (Investors)
Irina Koffler
646-970-4681
ikoffler@lifesciadvisors.com
Kleo Pharmaceuticals (Media)
Brian Dowd
(203) 643-9172
bdowd@kleopharmaceuticals.com
